Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with…
Media Release New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic…
MISSISSAUGA, Ontario, May 26, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for…
WATERTOWN, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology…
Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive…
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of…
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational…
Castellum, Inc. Announces $6 million Cost Reduction Plan Castellum, Inc. (the “Company”) (NYSE-American: CTM), announces cost reduction effort targeting at…
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a…
Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products…